A Single-Arm Phase II Trial of First-Line Paclitaxel in Combination with Lapatinib in HER2-Overexpressing Metastatic Breast Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A Single-Arm Phase II Trial of First-Line Paclitaxel in Combination with Lapatinib in HER2-Overexpressing Metastatic Breast Cancer

Published:2010 Issue:1-2 Volume:79 Page:129-135
ISSN:1423-0232
Container-title:Oncology
language:en
Short-container-title:Oncology

Author:

Jagiello-Gruszfeld Agnieszka,Tjulandin Sergei,Dobrovolskaya Natalya,Manikhas Alexey,Pienkowski Tadeusz,DeSilvio Michelle,Ridderheim Mona,Abbey Rowena

Publisher

S. Karger AG

Subject

Cancer Research,Oncology,General Medicine

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Effect of HER2 Status on Metaplastic Breast Cancer A Propensity Score-Matched Analysis;Frontiers in Endocrinology;2022-06-16

2. Dual targeting micelles loaded with paclitaxel and lapatinib for combinational therapy of brain metastases from breast cancer;Scientific Reports;2022-02-16

3. Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer;PLOS ONE;2021-08-04

4. Discovery of pan-ErbB inhibitors protecting from SARS-CoV-2 replication, inflammation, and lung injury by a drug repurposing screen;2021-05-16

5. Nanomedicine Interventions in Clinical Trials for the Treatment of Metastatic Breast Cancer;Applied Sciences;2021-02-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP